Neural mechanisms and management of obesity-related hypertension

被引:28
|
作者
Esler M.D. [1 ]
Eikelis N. [1 ]
Lambert E. [1 ]
Straznicky N. [1 ]
机构
[1] Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, St. Kilda Road Central
关键词
Obstructive Sleep Apnea; Essential Hypertension; Sympathetic Nerve; Sympathetic Nervous Activity; Human Obesity;
D O I
10.1007/s11886-008-0072-7
中图分类号
学科分类号
摘要
The sympathetic nervous system is activated in human obesity and in the analogous experimental obesity produced by overfeeding. The causes remain uncertain and may be multiple. The consequences include hypertension, probably attributable to activation of the sympathetic outflow to the kidneys, and, more disputed, insulin resistance. The pattern of sympathetic activation in normal-weight and obesity-related hypertension differs in terms of the firing characteristics of individual sympathetic fibers (increased rate of nerve firing in normal-weight hypertensives, increased number of active fibers firing at a normal rate in obesity-hypertension) and the sympathetic outflows involved. The underlying mechanisms and the adverse consequences of the two modes of sympathetic activation may differ. Should antihypertensive drug therapy in obesity-hypertension specifically target the existing neural pathophysiology? Such an approach can be advocated on theoretical grounds. Perhaps more important is the requirement that chosen antihypertensives do not cause weight gain or insulin resistance. © Current Medicine Group LLC 2008.
引用
收藏
页码:456 / 463
页数:7
相关论文
共 50 条
  • [21] Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications
    Graziela Z Kalil
    William G Haynes
    Hypertension Research, 2012, 35 : 4 - 16
  • [22] Obesity-Related Hypertension? Weighing the Evidence
    Kotchen, Theodore A.
    HYPERTENSION, 2008, 52 (05) : 801 - 802
  • [23] Treating obesity-related hypertension with surgery
    Livingston, E
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (04) : 443 - 445
  • [24] Effects of hydralazine in obesity-related hypertension
    Carroll, JF
    King, JW
    Cohen, JS
    FASEB JOURNAL, 2003, 17 (05): : A1236 - A1236
  • [25] Treatment strategies for obesity-related hypertension
    Reisin, Efrain
    CURRENT HYPERTENSION REPORTS, 2008, 10 (02) : 129 - 130
  • [26] Effect of adrenomedullin on obesity-related hypertension
    Mogi, Masaki
    HYPERTENSION RESEARCH, 2024, 47 (08) : 2221 - 2222
  • [27] Pathophysiology and treatment of obesity-related hypertension
    Chrysant, Steven G.
    JOURNAL OF CLINICAL HYPERTENSION, 2019, 21 (05): : 555 - 559
  • [28] Developmental origins of obesity-related hypertension
    Henry, Sarah L.
    Barzel, Benjamin
    Wood-Bradley, Ryan J.
    Burke, Sandra L.
    Head, Geoffrey A.
    Armitage, James A.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (09): : 799 - 806
  • [29] Factors Responsible for Obesity-Related Hypertension
    Kyungjoon Lim
    Kristy L. Jackson
    Yusuke Sata
    Geoffrey A. Head
    Current Hypertension Reports, 2017, 19
  • [30] Pharmacological Treatments for Obesity-Related Hypertension
    Esler, Murray D.
    Masuo, Kazuko
    CURRENT HYPERTENSION REVIEWS, 2010, 6 (02) : 92 - 99